



*Cell cycle pioneers
Improving patient lives
With orally available innovative medicines*

About Cyclacel www.cyclacel.com

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company has three orally-available product candidates in clinical development, for which Cyclacel has retained rights in most global markets. Through Cyclacel's ALIGN Pharmaceuticals subsidiary, the Company markets Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia in the United States. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

CLINICAL DRUG PIPELINE

Product Candidate	Indication	Ph 1	Ph 2	Ph 3
Sapacitabine	Acute myeloid leukemia (AML)	[Progressing through Ph 1, 2, and 3]		
	Myelodysplastic syndromes (MDS)	[Progressing through Ph 1, 2, and 3]		
	Non-small cell lung cancer (NSCLC)	[Progressing through Ph 1, 2, and 3]		
Seliciclib	Non-small cell lung cancer (NSCLC)	[Progressing through Ph 1, 2, and 3]		
	Nasopharyngeal (NPC)	[Progressing through Ph 1, 2, and 3]		
Sapacitabine + seliciclib	Solid tumors	[Progressing through Ph 1, 2, and 3]		
Sapacitabine * * Investigator-initiated	Chronic lymphocytic leukemia (CLL)	[Progressing through Ph 1, 2, and 3]		

A PIONEER IN CELL CYCLE BIOLOGY

Applying its core strength in cell cycle biology, Cyclacel is advancing a deep pipeline of small molecule drugs designed to stop uncontrolled cell division including three clinical stage compounds and several at preclinical stages. The Company's founder, Professor Sir David Lane, is a leading authority in cell cycle biology credited with the discovery of p53, one of the most commonly mutated tumor suppressor genes in patients with cancer. Cyclacel's Chief Scientist, Professor David Glover, is a recognized leader in mitosis and discoverer of the aurora and polo mitotic kinase families, essential cell cycle control mechanisms that regulate cancer cell division.

CYCLACEL QUICK FACTS

Founded 1996

Contact Details

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, # 1500
Berkeley Heights, NJ 07922
Tel: (908) 517-7330
Fax: (866) 271-3466

Cyclacel Ltd
1 James Lindsay Place
Dundee, Scotland DD1 5JJ, U.K.
Tel: +44 1382 206 062
Fax: +44 1382 206 067

Stock Listing

NASDAQ: CYCC (common), CYCCP (preferred)

MANAGEMENT

- Spiro Rombotis
President & Chief Executive Officer
- Paul McBarron
EVP, Finance & Chief Operating Officer
- Judy Chiao, M.D.
Vice President, Clinical Development & Regulatory Affairs
- Professor David Glover, Ph.D.
Chief Scientist
- Bob Sosnowski
Vice President, Marketing & Sales
- Susan Davis, Ph.D.
Director, Business Development



HIGHLIGHTS OF DRUG CANDIDATES IN CLINICAL TRIALS

SAPACITABINE ORAL CAPSULES (CYC682)

An orally-available nucleoside analogue with a dual mechanism; interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2-Phase

Clinical status: Currently being evaluated in the SEAMLESS Phase 3 trial in elderly patients with acute myeloid leukemia (AML) under a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration and Phase 2 trials in patients with hematological malignancies and solid tumors. Interim results from an ongoing, multicenter, Phase 1/2 clinical trial reported at the 2011 ASCO annual meeting highlighted the safety and effectiveness of sapacitabine administered sequentially with decitabine in elderly patients with AML. Thirty-day mortality from all causes was 4.5%; 60-day mortality from all causes was 9.5%. The overall response rate was 34.8%.

SELICICLIB ORAL CAPSULES (CYC202) & CYC065

Orally-available molecules that selectively target multiple cyclin-dependent kinases (CDKs) central to the process of cell division and cell cycle control, in particular CDK2, CDK5, CDK7 and CDK9

Clinical status: Top line results from APPRAISE, Cyclacel's Phase 2b, randomized discontinuation, double-blinded, placebo-controlled, study of oral seliciclib capsules as a third or more line treatment in patients with non-small cell lung cancer (NSCLC) showed that there was no difference between the seliciclib and placebo arms in terms of progression free survival (48 versus 53 days respectively), but an increase in median overall survival was observed favoring the seliciclib arm over the placebo arm (388 versus 218 days respectively).

CYC065, currently in investigational new drug (IND)-enabling studies, retains the specificity and mechanism of action of seliciclib, but has increased anti-proliferative potency, improved pharmaceutical properties, and new intellectual property protection. CYC065 has been shown to reverse resistance in trastuzumab-resistant breast cancer cells.

FINANCIAL HIGHLIGHTS (as of 11/02/11)

- 12-month Stock Price Range: \$0.36 to \$1.95
- Common Shares Outstanding: 54.2 million
- Cash and Equivalents (Q2 '11): \$20.6 million
- Market Capitalization: \$35 million

EXPECTED 2011 CORPORATE MILESTONES

- Initiation of the SEAMLESS pivotal Phase 3 study of sapacitabine in AML
- Presentation of additional sapacitabine data in hematological malignancies, both as a single agent and in combination with other anticancer agents
- Presentation of Phase 2 sapacitabine data in NSCLC
- Patient biomarker analysis from the APPRAISE Phase 2b randomized discontinuation study of seliciclib in patients with NSCLC

ANALYST COVERAGE

Brian Klein
Lazard Capital Markets, LLC

Jonathan Eckard
Howard Liang
Leerink Swann LLC

Joseph Pantginis
ROTH Capital Partners, LLC

INVESTOR/MEDIA CONTACT

Corey Sohmer csohmer@cyclacel.com

This document contains forward-looking statements with respect to business conducted by Cyclacel Pharmaceuticals, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. A discussion of those risks and uncertainties are more fully discussed under "Risk Factors" in the registration statements on Form 10-K and in the other reports of Cyclacel filed with the SEC. The compounds mentioned in this document including but not limited to sapacitabine, seliciclib and CYC116 are experimental drugs only for investigational use and are not approved for human use.